IMV Short Term CatalystsTo those of you who are new to this board or stopping by to check out what is going on with IMV and the recent activity upward, here is a quick short term outlook.
1. IMV recently consolidated shares on a 1 to 3.2 conversion in order to qualify for a NASDAQ listing. NASDAQ listing is likely days away as management mentioned at the AGM we likely will be trading prior to the June 3 Incyte data.
2. As I just mentioned, top line Phase 1b clinical results 300mg dose with Incyte in Ovarian at ASCO will be revealed on June 3rd. All signs point to very
positive results.
3. Mentioned in a Q&A article with management, IMV is about to announce a new partnership, which I'm almost postitive is not built into our current share price and nobody knows is really coming so expect a nice pop on this news.
"In fact, we plan to announce a new clinical trial in the next couple of months. We are going to start a basket trial in three to five indications with our lead product, DPX-Survivac, in combination with a PD-1. At this stage, we cannot confirm with whom we are going to work. We plan to go into these three to five indications because our target, survivin, is overexpressed in more than 20 indications in cancer. We want to start to tag and dose those new indications. The goal is to demonstrate whether our platform, combined with our product, has potential in more than just ovarian cancer. If it does, we will be able to increase the value for our shareholders."
Article link: https://www.streetwisereports.com/article/2018/05/16/cancer-in-the-crosshairs-imv-looks-to-deliver-immunotherapy-a-new-way.html
4. Preliminary phase 2 clinical results with Merck in DLBCL will be announced mid/end of summer.
5. Preliminary phase 2 clinical results with Merck in Ovarian cancer will be announced mid/end of summer.
Lots more to come in terms of news from IMV however this outlines just the very near term (next 3-4 months) of activity which will drive the SP higher.